Plain-English translation of NCT05365802 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging scan called PET to help doctors better understand and predict how interstitial lung disease will progress in individual patients. The scan looks for active scarring and inflammation in the lungs by detecting special cells called fibroblasts that are involved in tissue damage. Researchers believe this new imaging tool could help identify which patients are at highest risk and need more aggressive treatment.
Interstitial lung disease affects many people differently—some stay stable without treatment, while others get worse quickly even with medication. Doctors currently have difficulty predicting who will decline rapidly and who will stay stable. This trial exists to determine whether the new imaging scan can provide better clues about which patients are at highest risk, so treatment can be tailored more effectively.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the imaging tracer and then undergo a PET/CT scan that takes 20–50 minutes to complete. You would also have a high-resolution CT scan of your lungs. After that, researchers will follow your case and compare the scan results with any tissue samples obtained if you need a biopsy or surgery as part of your regular clinical care. The study involves no ongoing visits beyond the initial scans, unless you are already scheduled for surgery or biopsy.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States